PDS Biotech Names Colorectal Cancer Drug PDS0301 Lead Program; $11M Waits on FDA Filing
PDS Biotechnology (Nasdaq: PDSB) used its third-quarter report, released at 8 a.m. ET on Friday, Nov. 13, to keep its tumor-targeted interleukin-12 (IL-12) immunocytokine PDS0301 as the company's lead program. A second $11 million tranche from Nant …